Research Reports

Littany Lane Investments Analyst Initiates Coverage of CollabRx with Near Term Target of $2-$3.50

Thank You for Joining the most Reliable Source for Balanced Research Reports on Current Market Trends.

CollabRx Inc. (NASDAQ: CLRX)  Analyst Report can be found at bottom of page. But, before you dive into that allow us to tell you a little bit about ourselves.

As one of the largest trading groups/newsletters in the business we would like to direct you to the FAQ and about us sections of our corporate website to understand who we are and what we do. Also please read the full disclaimer at the bottom of this page.

http://smallcapspecialists.com/faqs/

http://smallcapspecialists.com/about-us/

We implore you to watch us and I promise you will immediately see the difference. We represent the highest quality small-cap companies with what we feel have the most near and long term potential in the market.

Our coverage includes Technology, FDA approval, biotech , energy, Cannabis and more. Most of these are listed NASDAQ, NYSE and AMEX as well as fully reporting OTCQB now and then.

Recent Winning Picks

We recently had the #1 gainer on the entire exchange two weeks in a row.

(NASDAQ: NXTD) November 20th, 2015 over 28% gains (#3 gainer on the exchange day 2 of coverage)

(NASDAQ: VGGL) November 12th, 2014 over 100% gains (#1 gainer on the exchange)

(NYSE: CANF) November 18th , 2014 over 145% gains (#1 gainer on the exchange)

(NASDAQ: VUZI) alerted November 4th,  2014 at $3.24/share currently trading at $6.20/share after a $24M investment from Intel. Uplisted Jan. 28th, 2015

Want to receive our alerts on time?

We have options:

1. Text “SmallCapIR” to 25827 with keyword

2. Join our Oracle Picks twitter feed by becoming a follower here:

 twitter icon

CLRX Analyst Report

The following report is provided only to attract new members to our site. We were not compensated in any way for the issuing of this analyst report.

It should be noted that this recent analyst coverage and price target does not include the potential revenues Medytox brings to the table should the merger be completed.

Use the following PDF link to view full report.

Published February 3rd, 2015

PDFicon

Disclaimer

By agreeing to this disclaimer it indicates you have read and understand the full disclaimer. You will receive the full research report and additional profiles, alerts and updates from Small Cap Specialists, LLC newsletters. All information provided on any websites owned or managed by Small Cap Specialists, LLC and/or our newsletter and/or any distributed publication and/or media delivered through and/or by Small Cap Specialists, LLC pertaining to investing, stocks, securities must be understood as information provided and not investment advice. None of the information provided in this website constitutes a recommendation that any investment is suitable for any person. We advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in any stock including those featured on any of Small Cap Specialists, LLC ’s (herein referred to as the “Group”) websites, publications, applications, software, or other branded media including but not limited to the websites owned or managed by Small Cap Specialists, LLC (herein referred to as “SCS Websites”).

No Tolerance SPAM Policy: We will not sell or re-distribute your Email to any 3rd party. If applicable, please unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails.

Small Cap Specialists, LLC HAS NEVER and WILL NEVER accept free trading shares on behalf of ANY companies listed on SCS Websites or in our email newsletter, or other Social Media.

We encourage all to read the SEC’s INVESTOR ALERT before reading our Newsletter.

http://www.sec.gov/oiea/investor-alerts-bulletins/ia_newsletters.html#.U58yGvldXzI

All information provided regarding the companies featured on SCS Websites is provided in public forums directly from the companies themselves and contained within the Issuers’ SEC filings, OTC Disclosure & News Service filings, news releases, company websites as well as other sources of publicly available information. The profiles of Issuers’ does not represent a solicitation or recommendation to buy, sell, or hold these or any other securities. The receiver of SCS Websites shall not create, under any circumstances, any implication that there has been no change in the affairs of the issuers’ profiled since the date of the review. The advertisements within SCS Websites are not to be construed as offers to purchase securities in the companies which may be the subject of such advertisements pursuant to federal or state law or the laws of any foreign jurisdiction.

Past performance may not be indicative of future results. Therefore, you should not assume that the future performance of any specific investment or investment strategy will be profitable or equal to corresponding past performance levels. Each investment decision you make should be determined with reference to the specific information available for such investment, and not based upon the success of past recommendations.

This website and information within the website contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in an any featured equities’ regulatory filings and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. Any forward-looking statements found on SCS Websites are made as of the date thereof and the Group undertakes no obligation to update such statements.

An investment in an OTC security is speculative and involves a high degree of risk. Many OTC securities are relatively illiquid, or “thinly traded,” which tends to increase price volatility. Illiquid securities are often difficult for investors to buy or sell without dramatically affecting the quoted price. In some cases, the liquidation of a position in an OTC security may not be possible within a reasonable period of time.

The Group (and our Media Publications/Products) is periodically compensated for describing certain securities of the issuers highlighted on SCS Websites. SmallCapIR’s parent company has not been compensated for marketing services in relation to CLRX. SmallCapIR’s parent company has been compensated forty thousand dollars for investor relations and media services of NXTD by red rock marketing services LLC. We have been previously compensated up to fifty five thousand dollars each for ir services of VGGL , VUZI and CANF by pride media LLC but not compensated for this particular release. In addition, in some instances the Group and SCS Websites’s affiliates, officers, directors and employees may also have bought or may buy, or have sold or may sell the securities discussed in SCS Websites and may profit in the event of a rise in value of those securities. Each investor must make that decision based on his or her circumstances and judgment of market conditions under the counsel of a licensed Financial Advisor, Broker, or Dealer.

The Group does not review, and is not responsible for confirming, the accuracy of documents pertaining to issuers that are publicly traded and information submitted to the Group for inclusion in SCS Websites. The issuers and their management are solely responsible for the accuracy of any information regarding their security that has been provided to the Group for dissemination in SCS Websites. INVESTORS ARE URGED TO CONFIRM THE ACCURACY OF ANY INFORMATION OBTAINED FROM SCS WEBSITES PRIOR TO MAKING ANY INVESTMENT DECISION.

The Group volunteers disclosure of company compensation pertaining to public companies’ securities. We DO NOT engage in private transactions which may involve; Restricted Securities, Convertible Liabilities, Options Contracts, Warrants, Subscriptions, Exception Specific Securities, Corporate Bonds, and other financial instruments.

Small Cap Specialists, LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission, FINRA, and is not a Broker/Dealer. The group does not engage in high frequency trading.